01 Emergence of gene and cell-based therapies for hemoglobinopathies The global market is shifting towards single administration gene therapies that aim to cure transfusion-dependent beta thalassemia, expanding the market growth. For instance, in December 2023, the U.S. FDA approved CASGEVY, an exagamglogene autotemcel cell therapy as the first approved cell therapy for sickle cell disease treatment. This trend represents a shift from chronic supportive care to one-time durable cell therapy treatment.
02 Expansion of newborn screening programs for hemoglobinopathies The growing implementation of newborn screening initiatives is a key trend driving earlier diagnosis and treatment adoption for hemoglobinopathies. For instance, in 2023, India launched the National Sickle Cell Anaemia Elimination Mission, which aims to secure about 70 million people in tribal and high-prevalence regions by 2025-2026, significantly increasing the diagnosis rate. This expansion is a major trend shifting from underdiagnosis to early disease screening, which, in turn, expands access to therapies.
May 2026 Vertex Pharmaceuticals expanded commercialization activities for Casgevy, a CRISPR-based gene therapy for sickle cell disease and transfusion-dependent beta thalassemia. The company continued strengthening treatment access through additional treatment center expansions.
March 2026 Bluebird bio expanded access initiatives for Lyfgenia, a gene therapy for sickle cell disease. The company focused on increasing availability of advanced genetic treatment options for patients with severe hemoglobinopathies.
January 2026 Agios Pharmaceuticals expanded its clinical development activities for mitapivat in rare blood disorders, including hemoglobinopathy-related conditions. The company continued evaluating therapies aimed at improving red blood cell function and reducing disease burden.
October 2025 Pfizer expanded research collaborations focused on gene therapy and rare hematology disorders. The initiatives support development of innovative treatment approaches for inherited blood conditions, including hemoglobinopathies.